Organ-on-a-chip tools that recapitulate human biology, physiology and pathology are urgently needed in applied science research and drug testing to expedite discoveries while reducing research costs and animal sacrifice. Unfortunately, most products incorporating circulation mimicking perfusion are too complicated for researchers to use, incompatible with many protocols and reads, and low-throughput. Our goal is to change this for ordinary lab personnel and for researchers across disciplines. We will make a researcher-centric product that does not require special skills or training for use, a tool that is flexible enough to serve diverse research objectives, and a tool that for pharmaceutical industry means a simple, low-cost solution for predictive drug testing. Lena Biosciences? perfused, human, multi-organ platform will revolutionize preclinical testing of first line therapy drugs that clear or metabolize slowly, saving pharmaceutical companies time and money while reducing human safety hazards. The platform will be made in a standard, screening-accessible format known to any user in life sciences, biotechnology and drug discovery for ease of use and user adoption. It will support perfused, three-dimensional organ models for physiologically closer drug delivery and distribution by mimicking drug distribution intra-tissue and intra-tissue resistance to drug transport. It will be especially well suited for in vitro testing of high molecular weight, humanized therapeutics that are administered to patients intravenously and retained in circulation for the period of weeks. Ultimately, the platform will also serve as a prognostic tool by providing concentrated cell secretome, proteome and metabolome to prevent severe reactions in human trials while facilitating identification of biomarkers, cellular and biochemical changes in response to drugs. The utility of this human platform will be demonstrated using three-dimensional organ models of lung cancer, breast cancer, brain and liver, and further validated by showing predictive in vitro efficacy and off-target toxicity testing of approved drugs.

Public Health Relevance

This perfused, human, multi-organ research platform will enable disease fingerprinting and drug testing in vitro. It will advance public health by enabling faster, low-cost testing of drug candidates for the ultimate safe and effective treatment of cancer, inflammatory, infectious, autoimmune, neurological and cardiovascular diseases.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44TR001286-03
Application #
9730683
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Hsiao, H Timothy
Project Start
2016-05-01
Project End
2020-06-30
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
3
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Lena Biosciences, Inc.
Department
Type
DUNS #
827555181
City
Atlanta
State
GA
Country
United States
Zip Code
30332